Market Cap Plummets Following Downward Revision of Key Product Sales Guidance

Alnylam Pharmaceuticals (ALNY), a leader in RNA interference (RNAi) technology, shocked the market by lowering its full-year sales guidance for its key product portfolio during its Q2 2026 earnings announcement. Alnylam (ALNY) reduced its combined annual sales forecast for Amvuttra (vutrisiran) and Onpattro (patisiran), its transthyretin amyloidosis (ATTR) treatments, from $4.4 billion to $4.7 billion to $4.2 billion to $4.5 billion. This unexpected downward revision caused the company's stock price to plummet approximately 30% in a single day, wiping out about $12 billion in market capitalization. While the reported earnings figures, with a non-GAAP EPS of $1.84, exceeded market expectations, concerns about future growth prospects triggered the sharp stock decline.

Pent-Up Demand Subsides and Patient Inflow Normalizes

The primary reason for the lowered sales guidance is the dissipation of initial pent-up demand in the transthyretin amyloid cardiomyopathy (ATTR-CM) market and the normalization of patient inflow. Amvuttra (Amvuttra) received FDA approval for the cardiomyopathy (ATTR-CM) indication on March 20, 2025, and experienced a temporary surge in sales as prescriptions poured in from patients awaiting a second-line treatment option. However, as the initial pent-up demand from both hereditary and wild-type cardiomyopathy patients rapidly subsided, the growth rate has stabilized. Consequently, Amvuttra's (Amvuttra) Q2 sales reached $1.012 billion, slightly below the market's expectation of $1.05 billion, making the guidance cut unavoidable.

Intensifying Three-Way Competition in the ATTR-CM Market

The global transthyretin amyloid cardiomyopathy (ATTR-CM) market, currently estimated at approximately $5.85 billion, is becoming increasingly competitive with the entry of existing standard-of-care treatments and new competing drugs. While Pfizer (PFE), with its Vyndaqel/Vyndamax (tafamidis), has established a strong market presence, BridgeBio Pharma (BBIO), with its Attruby (acoramidis), which received FDA approval on November 22, 2024, is rapidly gaining ground. In addition, Alnylam (ALNY)'s Amvuttra is facing fierce commercial competition from Wainua (eplontersen), jointly developed by AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS), for market share. With 80% of new prescriptions originating from the first-line treatment setting, the lowered guidance suggests that Alnylam (ALNY)'s pace of market dominance is slowing down.

Clinical Failure Overhang and the Challenge of Restoring Market Confidence

This downward revision of sales forecasts came shortly after the announcement on July 9th of the failure of Wainua (Wainua), a competing drug, in its Phase 3 CARDIO-TTRansform clinical trial, further amplifying market concerns. At that time, Wainua (Wainua) failed to demonstrate significant clinical benefit when administered as an add-on therapy to patients already taking Vyndaqel (Vyndaqel), raising fundamental questions about the efficacy of transthyretin (TTR) mRNA silencer-based drugs. Alnylam (ALNY) announced the signing of an exclusive commercialization partnership agreement with BeOne Medicines for China and Macau in conjunction with this earnings release, in an attempt to find a breakthrough, but it was not enough to offset the impact of the guidance cut. As a result, until the data from competitors are analyzed at the European Society of Cardiology (ESC) in late August, a conservative investment sentiment towards RNA interference (RNAi) therapies is likely to persist.